C-Rad AB (LTS:0R44) Beta: -0.0767 (As of Jun. 25, 2026)


LTS:0R44 C-Rad AB LTS:0R44
83 GF Score
Price kr35.90
GF Value kr33.44
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is C-Rad AB Beta?

C-Rad AB LTS:0R44 83 Beta is -0.0767 as of Jun. 25, 2026. GuruFocus rates LTS:0R44 with a GF Score™ of 83/100 and a GF Value™ of kr33.44 (Fairly Valued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), C-Rad AB's Beta is -0.0767.


C-Rad AB  (LTS:0R44) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


C-Rad AB Beta Related Terms


C-Rad AB Beta Historical Data

* Premium members only.

The historical data trend for C-Rad AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C-Rad AB Beta Chart

C-Rad AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.05 -0.35 0.27

C-Rad AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 0.08 0.29 0.27 -0.05

LTS:0R44 vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, C-Rad AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C-Rad AB Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Beta distribution charts can be found below:

* The bar in red indicates where C-Rad AB's Beta falls into.


LTS:0R44
83GF Score
C-Rad AB LTS:0R44
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C-Rad AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0767 mean?
C-Rad AB (LTS:0R44) has a Beta of -0.0767 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for C-Rad AB and its competitors.
Is C-Rad AB's Beta too high?
C-Rad AB's current Beta is -0.0767. Overall, C-Rad AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Beta compare to ABT and SYK?
C-Rad AB's Beta of -0.0767 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for C-Rad AB and its competitors. C-Rad AB's current Beta is -0.0767. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.44, compared to a current price of kr35.90 — trading 7.4% above its estimated fair value. The current Beta is -0.0767. C-Rad AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Beta is -0.0767 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C-Rad AB (LTS:0R44) Overvalued in 2026?

Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued. The current stock price of kr35.90 is trading 7.4% above its estimated GF Value™ of kr33.44. GuruFocus considers C-Rad AB to be Fairly Valued.

Key valuation signals for LTS:0R44:

  • Beta: -0.0767
  • GF Value™: kr33.44 vs. price of kr35.90 (7.4% above fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


C-Rad AB Business Description

Other Exchanges CRAD B:Sweden24C:Germany
Address Sjukhusvagen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
83GF Score

Get the complete analysis for LTS:0R44

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr35.90
Price
kr33.44
GF Value